November 14th 2023
Expensive gene therapy has grabbed the headlines, but three promising drugs that work in the coagulation pathway are in late-stage development.
October 11th 2023
Two drugs that target the c-MET protein are in phase 3 trials.
September 5th 2023
Although Aduhelm stumbled, Leqembi has received full FDA approval, and Eli Lilly has reported positive results for donanemab.
August 8th 2023
Selective estrogen receptor degraders are vying to join aromatase inhibitors and selective estrogen receptor modulators as therapy after the initial treatment of breast cancer.
July 13th 2023
The approval of Mounjaro (tirzepatide) for weight loss could be a tipping point for weight-loss drugs.
What’s on the horizon for drug development in 2021?
The industry is adjusting to the pandemic, but FDA approvals could dip this year. Several new drugs for atopic dermatitis may get the agency’s green light.
2020 drug approvals: not bad, considering
Pre-pandemic momentum helped keep the number of novel therapies approved by the FDA high, and then COVID-19 tested just how fast the pipeline could adjust and expand.
Positive results for Darzalex, Jakavi to be reported at ASH
Results of APOLLO and REACH3 trials are scheduled for presentation at the American Society of Hematology meeting next month are expected to garner attention.
Alzheimer’s Research Shifting to Tau as a Target
Negative results for semorinemab have deflated some of the hopes for a tau as a target, although a winning strategy Alzheimer's may involve hitting several targets at once, including tau.
FDA Updates: Ofatumumab for MS, More Data Needed for Filgotinib in RA, Hearing Set for ALKS 3831
FDA actions for the week ending August 21, 2020, include a hearing set for a drug that could limit weight gain often associated with treatment for serious mental illness.
FDA Updates: Treatment for Duchenne Mutation, Gilead Seeks Remdesivir Approval, Data on ALKS 3831
Actions from FDA this week include approval of a second targted treatment for a Duchenne muscular dystrophy mutation, and filings in COVID-19 and blood disorders.
FDA Updates: Blood Cancers, Orphan Drug Designations Get Priority
In a busy week, FDA approved ground-breaking therapies in hematologic cancers and issued Orphan Drug designations in areas of significant unmet need.
New Drugs Take Aim at Autoimmune Diseases
Potential agents to battle inflammation and other processes move through development pipeline.
Our Coverage of the Race to Develop a COVID-19 Vaccine
As several COVID-19 vaccine candidates are now in the late phase of clinical trials, MHE is sharing a few stories that have covered the infamous virus' vaccine development journey.
Sandoz, Boehringer Ingelheim Battle Biosimilar Misinformation
Biosimilar misinformation takes many forms, some of it institutionalized in the form of word usage and some of it deliberately disparaging, 2 executives of Sandoz and Boehringer Ingelheim contend.
Famed AIDS Researcher Finds That the Sickest Patients Could Hold the Key to Beating COVID-19
Dr. David Ho, who developed the HIV cocktail, has isolated antibodies he says could be used to create treatments for COVID-19.
How Will Real-World Evidence Help Drive Solutions for COVID-19?
How real-world evidence will help FDA develop a vaccine.
Heart Drug Updates: Fast Track for Farxiga after MI, Brilinta Plus Aspirin After Stroke or TIA, NDA for Vericiguat
Heart disease drugs were in the news this week.
It's Possible for Those Who Practice and Pay for Precision Oncology to Catch Up to Speed of Innovation
The fast-evolving field of precision medicine offers the promise of more effective treatments and better outcomes, and it’s time that we collaborate to keep outdated clinical and reimbursement practices from slowing it down.
Is Combination Therapy on the Horizon in Diabetic Macular Edema?
Patients with diabetic macular edema whose vision remains impaired even with the best available treatments may soon have a combination therapy.
FDA Updates: Brilinta’s Priority Review in Stroke; Biogen’s Alzheimer’s BLA; Mytesi IND in Cancer Care
Drug development in key areas of unmet need hit milestones this week, with Biogen, AstraZeneca, and Jaguar Health announcing regulatory steps with the FDA.
Express Scripts Report: Top Drug Classes Driving Spending Growth
Express Scripts’ annual Drug Trend Report highlights top contributors to prescription drug spending in 2019.
The Most Valuable Pipeline Drugs For 2020
Here are the top drugs expected to be approved this year and their financial impact.
Top Women’s and Men’s Cancer Treatment Developments
From breast cancer to prostate cancer, the state of oncology care and how it will evolve.
Life-Altering Gene Therapy Pipeline Poses Challenges
What to expect for these high-dollar drugs.
What You Need to Know About the Vaccine Pipeline
The vaccines that could make a big impact on healthcare, from radical new flu vaccines to simplified meningococcal vaccine regimens.
Five Ways Diabetes Treatments are Changing
The disease management and insurer initiatives changing the diabetes landscape.
Novel Therapies Mitigate High-Cost Rheumatoid Arthritis Treatment
The latest in RA therapies, and what you can expect from the pipeline.
7 Therapeutic Game-Changers in 2019
Managed Healthcare Executive asked top experts their predictions for the top game-changing therapies. Here’s what they said.
Top 5 Therapeutic Areas for 2019
The biggest drug categories and medications set for approval this year.
Top Blockbuster Drugs for 2019
Major blockbuster drugs slated for launch in 2019 are expected to have a significant impact on treating certain cancers, diabetes, peanut allergies, and other conditions.
Three Vaccine Developments Healthcare Execs Should Watch
Vaccines are an important part of creating “herd immunity” to keep infectious diseases in check. Here are three vaccine developments that have far reaching implications for public health.
Substantial Lymphoma Treatment Progress: What Health Execs Should Know
Gwen Nichols, MD, chief medical officer of the Leukemia & Lymphoma Society, offers a quick overview of current developments as well as a look forward.
News You Should Know: 3 Takeaways from Top Managed Care Articles May
Have two minutes? Listen to this quick podcast for critical takeaways from three of our top articles.
How Payers are Responding to Growing Orphan Drug Costs
2 Clarke Drive Cranbury, NJ 08512